<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01276275</url>
  </required_header>
  <id_info>
    <org_study_id>D5130N00010</org_study_id>
    <nct_id>NCT01276275</nct_id>
  </id_info>
  <brief_title>Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel</brief_title>
  <official_title>A Pharmacoepidemiological Study to Examine Patient Characteristics, Drug Utilization Pattern and Crude Incidence Rates of Selected Outcomes in New Users of Ticagrelor, Clopidogrel and Prasugrel in National Swedish Registries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to describe patient characteristics and drug usage among patients
      that are prescribed ticagrelor for the first time and to compare them with patients who are
      prescribed clopidogrel and prasugrel for the first time.

      A further purpose is to ascertain and estimate the crude incidence rate of bleeding,
      arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout among
      new users in the three cohorts of ticagrelor, clopidogrel and prasugrel.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Drug utilization: Description of patient characteristics and drug usage</measure>
    <time_frame>Up to one year after entry into study cohort</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up of safety outcomes: First occurrence of bleeding, arrhythmias, heart failure, acute renal failure, acute liver failure, dyspnoea and gout</measure>
    <time_frame>Up to one year after entry into study cohort.</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">7200</enrollment>
  <condition>Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout</condition>
  <arm_group>
    <arm_group_label>Exposure Group 1</arm_group_label>
    <description>First time users of ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exposure Group 2</arm_group_label>
    <description>First time users of clopidogrel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exposure Group 3</arm_group_label>
    <description>First time users of prasugrel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risk of selected safety events</intervention_name>
    <description>First time users of ticagrelor, clopidogrel and prasugrel, respectively</description>
    <arm_group_label>Exposure Group 1</arm_group_label>
    <arm_group_label>Exposure Group 2</arm_group_label>
    <arm_group_label>Exposure Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients aged 20 to 84 years before their first study drug dispension (start date) will
        be included in the study. The study period will start the first month after ticagrelor
        market introduction in Sweden (the first of June 2011),
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First time users of ticagrelor, clopidogrel and prasugrel, respectively

        Exclusion Criteria:

          -  Individuals with more than one of above three antiplatelet drugs dispensed the same
             day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helle Kieler, MD, PhD, Assoc Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Pharmacoepidemiology, Karolinska Institute, Stockholm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=488&amp;filename=SynopsisD5130N0010.pdf</url>
    <description>SynopsisD5130N0010</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2011</study_first_submitted>
  <study_first_submitted_qc>January 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2011</study_first_posted>
  <last_update_submitted>March 30, 2016</last_update_submitted>
  <last_update_submitted_qc>March 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute coronary syndrome, thienopyridine, epidemiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

